XML 52 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Events
12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events

17. Subsequent Events

The Company appointed Gil M. Labrucherie, CFA, J.D. as the Chief Financial Officer (“CFO”), principal financial officer and principal accounting officer of the Company, effective January 6, 2025. On February 7, 2025, the Compensation Committee of the Board granted 0.2 million shares of stock options to the CFO.

In February 2025, the Company announced its decision to discontinue the clinical study of SEP-786. There was no impact to the assets and liabilities reported on the Company's balance sheets as a result of the discontinuation.